Don’t miss the 11th World Congress of Melanoma and 21st EADO Congress
Marco Donia shared a post by Melanoma World Society, on LinkedIn:
“Neoadjuvant or Perioperative Immunotherapy: New Standard of Care for Macroscopic, Resectable Melanoma Stage ≥IIIB.”
Quoting Melanoma World Society‘s post:
“Latest Publication Alert in The Lancet Oncology!
We are proud to announce the publication of an international survey conducted under the auspices of the Melanoma World Society – MWS, the EADO – European Association of Dermato-Oncology, and supported by HERACLIN GmbH. Featuring insights from 104 melanoma experts across 24 countries and 80+ institutions, this study sheds light on the adoption of neoadjuvant and perioperative therapies for melanoma metastases in clinical practice, providing key perspectives ahead of the NADINA Phase III results.
Key Findings:
– 89% of experts advocate for the immediate adoption of neoadjuvant or perioperative therapies for melanoma with locoregional metastases, even before regulatory approvals.
– The hashtag#SWOGS1801 regimen was identified as the preferred approach for immediate implementation, thanks to its established reimbursement and ease of application.
– 100% of respondents deemed these therapies safe for resectable locoregional disease (AJCC stage III).
This study highlights the importance of real-world data in shaping clinical guidelines and addressing regulatory and reimbursement challenges. We look forward to seeing how these findings evolve in light of the NADINA Phase III data!
Join Us in Athens!
Don’t miss the 11th World Congress of Melanoma and 21st EADO Congress, the world’s largest gathering in dermato-oncology, taking place April 3–5, 2025, in Athens, Greece. Connect with global experts and be part of shaping the future of melanoma research and care. Click here for more information.
Authors: Axel Hauschild, Claus Garbe, Paolo Antonio Ascierto, Lev Demidov, Brigitte Dreno, Reinhard Dummer, Alexander Eggermont, Ana-Maria Forsea, Christoffer Gebhardt, Jeffrey E Gershenwald, Omid Hamid, Christoph Hoeller, Lidija Kandolf, Roland Kaufmann, John M Kirkwood, Celeste Lebbé, Georgina V Long, Josep Malvehy, Salvador Martin-Algarra, Grant McArthur, Bart Neyns, Erika Richtig, Caroline Robert, Dirk Schadendorf, Richard Scolyer, Vernon K Sondak, Alberto Wainstein, Michael Weichenthal, Paolo Nuti.
Marco Donia is a Senior Consultant, Clinician-Scientist and Junior Research Group Leader (TIL group) at the Department of Oncology and Center for Cancer Immune Therapy, University of Copenhagen Herlev Hospital, Denmark. He serves as an Associate Professor in Clinical Oncology at the University of Copenhagen.
Donia is also a clinical oncologist treating patients with cancer immunotherapy. His research group is currently investigating new immune-regulatory circuits in PD-1/PD-L1 resistant tumors.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023